Funding for this research was provided by:
Karyopharm Therapeutics
Article History
Accepted: 13 July 2021
First Online: 9 August 2021
Declarations
:
: Funding was provided by Karyopharm Therapeutics.
: H. Leong is an employee of Karyopharm Therapeutics. M. Dolph and G. Tremblay are employees of Purple Squirrel Economics, which received funding from Karyopharm Therapeutics to conduct this study.
: Not applicable.
: Not applicable.
: Not applicable.
: Data from the BOSTON trial can be found in “Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial” by Grosicki et al. [CitationRef removed].
: Not applicable.
: MD and GT were responsible for data analyses and data interpretation and participated in the drafting and revising of the manuscript. All authors were responsible for the study conception and design and participated in data interpretation and reviewed the manuscript.